As shown in Figure 2, the key pillars of pharmacological treatments for CKD and related CVD are RAAS inhibition with ACE inhibitor or angiotensin receptor blocker, SGLT‐2 inhibitors, GLP‐1 receptor agonists and nsMRAs. Here, SLC5A2 is linked to chronic kidney disease.